Healthcare / Drug Manufacturers - Specialty & GenericTSXV
$0.49
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-10.1M · quality 63.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$40M
P/E
N/A
•EV/EBITDA
N/A
•ROE
632.6%
↑Gross Margin
26.8%
↓Debt/Equity
-2.28
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+32.5%
FCF CAGR
—
FCF margin
-2062.8%
FCF / Net income
0.29x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $481000.0 · net income $-33.8M · FCF $-9.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $481000.00 | $481000.00 | $351000.00 | $298000.00 | $207000.00 |
| Net Income | $-33.8M | $-33.8M | $-42.6M | $-24.7M | $-23.5M |
| EBITDA | $-32.2M | $-32.2M | $-42.1M | $-15.4M | $-17.1M |
| EPS | -0.47 | -0.47 | -0.76 | -0.35 | -0.34 |
| Gross Margin | 26.8% | 26.8% | 48.7% | -77.9% | 69.1% |
| Operating Margin | -3056.1% | -3056.1% | -4898.0% | -5468.1% | -10999.5% |
| Net Margin | -7028.1% | -7028.1% | -12134.2% | -8274.2% | -11330.9% |
| Balance Sheet | |||||
| Debt/Equity | -2.28 | -2.28 | 0.42 | 7.36 | — |
| Current Ratio | 0.10 | 0.10 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.9M | $-9.9M | $-18.2M | $-10.1M | $-21.8M |
| Returns | |||||
| ROE | 632.6% | 632.6% | -184.3% | -520.1% | — |
| Valuation | |||||
| P/B | — | — | 2.16 | 12.52 | — |
| Growth & Yield | |||||
| Revenue Growth | 37.0% | 37.0% | 17.8% | 44.0% | — |
| EPS Growth | 38.2% | 38.2% | -115.3% | -5.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-35.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.76 → -0.47
Residual
-35.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.